In Silico Repurposing of Approved Drugs Against Multidrug-Resistant Klebsiella pneumoniae
DOI:
https://doi.org/10.5281/zenodo.22638153Keywords:
drug repurposing, Klebsiella pneumoniae, molecular docking, network pharmacology, antimicrobial resistanceAbstract
Background: Multidrug-resistant (MDR) Klebsiella pneumoniae, a WHO critical-priority pathogen, drives substantial global
mortality and outpaces conventional antibiotic development. Objective: This review synthesises published in silico
drug-repurposing, virtual-screening and network-pharmacology studies targeting MDR K. pneumoniae. Methods: A narrative
review of docking, molecular-dynamics and network-pharmacology studies identified via PubMed, Google Scholar, Crossref and
bioRxiv, each individually verified for authorship, journal and DOI before inclusion. Findings: Subtractive-genomics and
structure-based docking campaigns nominated LpxC, NDM-1, DapB and DNA adenine methyltransferase as druggable targets,
yielding repurposed hits including an FDA-library metallo-β-lactamase inhibitor and phytochemical DapB ligands. Repurposed
non-antibiotic drugs, including flufenamic acid and colistin itself, restored efficacy by inhibiting PmrB signalling and RND efflux,
while rifaximin was repositioned against the virulence regulator RfaH. Network-pharmacology and multi-target natural-product
screens implicated PI3K/AKT-MAPK signalling and biofilm-associated targets. Broad-spectrum virtual screening and empirical
FDA-library screening independently validated repurposing feasibility. Conclusions: Computational repurposing has generated
diverse, mechanistically distinct candidates against MDR K. pneumoniae, but translation requires standardised validation,
resistance surveillance and pharmacokinetic profiling before clinical application.
References
Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, Ouellette M, Outterson K, Patel J, Cavaleri M, Cox EM, Houchens CR, Grayson ML, Hansen P, Singh N, Theuretzbacher U, Magrini N. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318-327. doi:10.1016/S1473-3099(17)30753-3. PMID:29276051.
Murray CJL, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, Han C, Bisignano C, Rao P, Wool E, Johnson SC, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629-655. doi:10.1016/S0140-6736(21)02724-0. PMID:35065702.
Paczosa MK, Mecsas J. Klebsiella pneumoniae: Going on the Offense with a Strong Defense. Microbiol Mol Biol Rev. 2016;80(3):629-661. doi:10.1128/MMBR.00078-15. PMID:27307579.
Ahmad S, Navid A, Akhtar AS, Azam SS, Wadood A, Pérez-Sánchez H. Subtractive Genomics, Molecular Docking and Molecular Dynamics Simulation Revealed LpxC as a Potential Drug Target Against Multi-Drug Resistant Klebsiella pneumoniae. Interdiscip Sci. 2019;11(3):508-526. doi:10.1007/s12539-018-0299-y.
Shailaja S, Harshitha N, Fasim A, More SS, Das Mitra S. Identification of a potential inhibitor for New Delhi metallo-β-lactamase 1 (NDM-1) from FDA approved chemical library- a drug repurposing approach to combat carbapenem resistance. J Biomol Struct Dyn. 2023;41(16):7700-7711. doi:10.1080/07391102.2022.2123402. PMID:36165602.
Mahur P, Sharma A, Singh AK, Muthukumaran J, Jain M. Computational Exploration of Limonin as a Potential Inhibitor of DapB in Klebsiella pneumoniae. Chem Biodivers. 2024;22(2):e202402053. doi:10.1002/cbdv.202402053.
Mohd Omeershffudin UN, Kumar S. Antimicrobial resistance in Klebsiella pneumoniae: identification of bacterial DNA adenine methyltransferase as a novel drug target from hypothetical proteins using subtractive genomics. Genomics Inform. 2022;20(4):e47. doi:10.5808/gi.22067.
Phanus-umporn C, Anuwongcharoen N, Chatupheeraphat C, Kaewsai N, Eiamphungporn W. Repurposing flufenamic acid as a putative PmrB-directed adjuvant to restore colistin activity in Klebsiella pneumoniae. Microbiol Spectr. 2026;14(4). doi:10.1128/spectrum.03620-25.
Sharma R, Yeshwante S, Bui NM, Carbone V, Hicks L, Blough BE, Velkov T, Rao GG. A novel role for colistin as an efflux pump inhibitor in multidrug-resistant Klebsiella pneumoniae. Sci Rep. 2025;15(1):34612. doi:10.1038/s41598-025-18206-4.
Ashraf A, Choudhary A, Khan MA, Noor S, Islam A, Hassan MI. Repurposing rifaximin against Klebsiella pneumoniae via targeting of transcription anti-termination protein RfaH for novel antimicrobial development. Biochem Biophys Res Commun. 2025. doi:10.1016/j.bbrc.2025.152864. PMID:41232378.
Man T, Yu H, Li L, Nie W, Wang C. Integrative network pharmacology and experimental validation of multi-target synergy against multidrug-resistant Klebsiella pneumoniae via PI3K/AKT-MAPK pathway disruption. Naunyn Schmiedebergs Arch Pharmacol. 2026;399(4):5157-5171. doi:10.1007/s00210-025-04765-w.
Sajal H, Mohan A, Ravi V, Anjali K, Raju R, Rehman N, Nadh AG. Computational identification of multi-target natural compounds from Sesbania grandiflora as potential therapeutic agents against Klebsiella pneumoniae. Sci Rep. 2026;16(1):7782. doi:10.1038/s41598-026-37613-9.
Spyrakis F, Santucci M, Maso L, Cross S, Gianquinto E, Sannio F, Verdirosa F, De Luca F, Docquier JD, Cendron L, Tondi D, Venturelli A, Cruciani G, Costi MP. Virtual screening identifies broad-spectrum β-lactamase inhibitors with activity on clinically relevant serine- and metallo-carbapenemases. Sci Rep. 2020;10(1):12763. doi:10.1038/s41598-020-69431-y.
Peyclit L, Baron SA, Hadjadj L, Rolain JM. In Vitro Screening of a 1280 FDA-Approved Drugs Library against Multidrug-Resistant and Extensively Drug-Resistant Bacteria. Antibiotics (Basel). 2022;11(3):291. doi:10.3390/antibiotics11030291.
Nordmann P, Poirel L. Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria. Clin Infect Dis. 2019;69(Suppl 7):S521-S528. doi:10.1093/cid/ciz824. PMID:31724045.
Bush K, Bradford PA. Epidemiology of β-Lactamase-Producing Pathogens. Clin Microbiol Rev. 2020;33(2):e00047-19. doi:10.1128/CMR.00047-19. PMID:32102899.
Podschun R, Ullmann U. Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. Clin Microbiol Rev. 1998;11(4):589-603. doi:10.1128/CMR.11.4.589. PMID:9767057.
Russo TA, Marr CM. Hypervirulent Klebsiella pneumoniae. Clin Microbiol Rev. 2019;32(3):e00001-19. doi:10.1128/CMR.00001-19. PMID:31092506.
Wyres KL, Lam MMC, Holt KE. Population genomics of Klebsiella pneumoniae. Nat Rev Microbiol. 2020;18(6):344-359. doi:10.1038/s41579-019-0315-1.
van Duin D, Doi Y. The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence. 2017;8(4):460-469. doi:10.1080/21505594.2016.1222343. PMID:27593176.
Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, Doi Y, Tian G, Dong B, Huang X, Yu LF, Gu D, Ren H, Chen X, Lv L, He D, Zhou H, Liang Z, Liu JH, Shen J. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016;16(2):161-168. doi:10.1016/S1473-3099(15)00424-7. PMID:26603172.
Munita JM, Arias CA. Mechanisms of Antibiotic Resistance. Microbiol Spectr. 2016;4(2). doi:10.1128/microbiolspec.VMBF-0016-2015.
Stokes JM, Yang K, Swanson K, Jin W, Cubillos-Ruiz A, Donghia NM, MacNair CR, French S, Carfrae LA, Bloom-Ackermann Z, Tran VM, Chiappino-Pepe A, Badran AH, Andrews IW, Chory EJ, Church GM, Brown ED, Jaakkola TS, Barzilay R, Collins JJ. A Deep Learning Approach to Antibiotic Discovery. Cell. 2020;180(4):688-702.e13. doi:10.1016/j.cell.2020.01.021. PMID:32084340.
Wong F, Zheng EJ, Valeri JA, Donghia NM, Anahtar MN, Omori S, Li A, Cubillos-Ruiz A, Krishnan A, Jin W, Manson AL, Friedrichs J, Helbig R, Hajian B, Fiejtek DK, Wagner FF, Soutter HH, Earl AM, Stokes JM, Renner LD, Collins JJ. Discovery of a structural class of antibiotics with explainable deep learning. Nature. 2024;626(7997):177-185. doi:10.1038/s41586-023-06887-8. PMID:38123686.
Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455-461. doi:10.1002/jcc.21334.
Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7:42717. doi:10.1038/srep42717. PMID:28256516.
Alcock BP, Raphenya AR, Lau TTY, Tsang KK, Bouchard M, Edalatmand A, Huynh W, Nguyen ALV, Cheng AA, Liu S, Min SY, Miroshnichenko A, Tran HK, Werfalli RE, Nasir JA, Oloni M, Speicher DJ, Florescu A, Singh B, Faltyn M, Hernandez-Koutoucheva A, Sharma AN, Bordeleau E, Pawlowski AC, Zubyk HL, Dooley D, Griffiths E, Maguire F, Winsor GL, Beiko RG, Brinkman FSL, Hsiao W, Domselaar GV, McArthur AG. CARD 2020: antibiotic resistome surveillance with the comprehensive antibiotic resistance database. Nucleic Acids Res. 2020;48(D1):D517-D525. doi:10.1093/nar/gkz935. PMID:31665441.
